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Mesangiocapillary glomerulonephritis (MCGN) with "dense
deposits" in the basement membranes of the kidney. R. Vargas,
K. Thomson, D. Wilson, J. S. Cameron, D. R. Turner, D. Gill,
C. Chantler and C. S. Ogg. Departments of Pathology, Medicine
and Paediatrics, Guy's Hospital, London. Among 125 patients
with mesangiocapillary glomerulonephritis, 19 showed con-
tinuous intramembranous "dense deposits". Most were children
or young adults, many already with renal functional impairment,
with arterial hypertension, a nephrotic syndrome and profuse,
nonselective proteinuria. Some presented already in advanced
chronic renal failure. Two patients had partial lipodystrophy.
Twelve had a consistently low plasma concentration of C3; only
three, however, had a low plasma C4 concentration initially,
which rose and then remained normal. The C3NeF was positive
in nine out of 13 cases and plasma Clq was normal in 8 out of
11 cases investigated. Eight out of 11(6 of them with low plasma
C3) showed C3 deposition by immunofluorescence in the
glomeruli (linear in the glomerular basement membrane in
3 cases), as well as in Bowman's capsule and tubular basement
membranes; IgG, IgA, C4 and Clq were negative in all, whereas
1gM and fibrin were weakly positive in three and eight cases,
respectively. Eight patients went into terminal renal failure over
an average of 33 months and required hemodialysis or trans-
plantation; so far two patients have died, one after renal trans-
plantation; and one while receiving long-term hemodialysis.
Two patients are alive with an allograft, and four are alive on
regular dialysis treatment. Two patients showed rapidly progres-
sive renal failure with extensive, occluding crescents on renal
biopsy and were treated with prednisolone, azathioprine, di-
pyridamole and anticoagulant treatment. Nine others are alive
on no specific treatment; only three of these 11 patients have a
glomerular filtration rate (GFR) of less than 80 mI/mm. MCGN
with intramembranous "dense deposits" is an uncommon pat-
tern of renal response to injury, which involves activation of the
alternate pathway of the complement system, and has a poor
short-term prognosis. The association with partial lipodystrophy
and C3-splitting activity suggests a primary complement
abnormality.
Immune-complex-mediated mouse malaria nephropathy. C. R.P.
George and J. S. Cameron. Department of Medicine, Guy's
Hospital, London. Adult male mice were inoculated intraperitone-
ally with I x 10 Plasmodium berghei yoellii parasites and cohorts
of animals sacrificed at daily intervals. Animals of both TO and
A2G strains were used, since Petty, Steward and Soothill (Clin
Exp Immunol 12:231, 1972) have shown them to produce anti-
body of high and low affinity, respectively. Study of renal
histology showed the development of intraglomerular (predomi-
nantly mesangial) cell proliferation associated with granular mes-
angial deposition of immunoglobulins and C3 in all animals of
both strains by day 8. In ensuing weeks immunoglobulin deposi-
tion also occurred in glomerular capillary basement membranes.
The development and course of the renal disease was correlated
with circulating antigen (malaria parasite) and antibody levels.
Treatment with prednisolone, cyclophosphamide, azathioprine,
dipyridamole, sulphinpyrazone or warfarin from the first day of
infection failed to prevent or modify the renal disease, whereas
elimination of the antigen with chioroquine did prevent develop-
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ment of the nephropathy. It is therefore concluded that 1)
mouse malaria nephropathy is a convenient and highly repro-
ducible model of human immune-complex glomerulonephritis,
and 2) in the treatment of immune complex renal disease, elim-
ination of the antigen will cure the disease, whereas corti-
costeroid, immunosuppressive and antithrombotic therapy fails
to do this if antigenemia persists.
Observations on oliguria in the anesthetized dog. Mary L.
Forsling and Elisabeth Ullmann. Departments of Physiology,
Middlesex Hospital Medical School and Medical College of St.
Bartholomew's Hospital, London. Oliguria during anesthesia and
surgery is the result of several identifiable forms of stress, which
activate several separate mechanisms including increased dis-
charge of antidiuretic hormone (ADH) and increased secretion
of catecholamines. Contrary to accepted opinion we found that,
irrespective of the anesthetic used, a normal water diuresis can be
induced in anesthetised dogs, provided stresses which elicit ADH
release are carefully avoided. These are a) "pain", caused by
operative trauma under inadequate anesthesia, b) hypotension
and c) arterial hypoxia. Failure to induce a water diuresis, or
subsequent oliguria was always related to one, or a combination,
of these stresses. It proved much easier to induce and maintain a
"water" diuresis if anesthesia was deep rather than light. Oliguria
was more common when halothane was the anesthetic; but under
halothane the dogs had a lower blood pressure, a greater ten-
dency to systemic hypoxia and were more lightly anesthetised
than dogs anesthetised by other methods. In contrast to several
reports, we found that exogenous ADH (Pitressin) in doses
adequate in the conscious animal, inhibited diuresis during an-
esthesia, provided it was a true "water" and not an "osmotic"
diuresis. Pain and hypotension have long been known to provoke
ADH release in conscious dog and man; hypoxia as a stimulus
has so far received little attention, since it is rarely present in
conscious animals, and because strict blood gas control during
animal surgery is still uncommon. In our study direct assay of
arginine vasopressin in plasma demonstrated that breathing
l0% 0 in N2 for 15 mm led to a large increase in plasma ADH
and prolonged oliguria, together with a rise of blood pressure.
In dogs pretreated with guanethidine, however, plasma ADH
did not rise during hypoxia, an intriguing finding not yet ex-
plained. All the stresses mentioned are known to increase sym-
pathetic nerve activity. The pattern of urine flow and concentra-
tion by itself did not enable us to distinguish clearly between the
separate oliguric effects of ADH and catecholamines which may
be additive in hypoxia. The precise role of the latter in stress
oliguria remains to be assessed when arterial catecholamine con-
centration can be accurately measured, which may soon be
possible.
Renal biopsy in acute renal failure. J. D. Sraer, A. Kanfer,
J. Marsac, F. Mignon, L, Morel-Maroger, G. Richet and J.
Whitworth.1 Service de Nephrologie, Hôpital Tenon, Paris. We
have made a retrospective analysis of the clinical data and renal
histological findings from 145 patients with acute renal failure
1 Present address: Guy's Hospital, London.
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who underwent renal biopsy. These patients formed 12% of all
those with acute renal failure seen during the period 1966—1973.
Indications for renal biopsy were 1) oligoanuria persisting longer
than three weeks; 2) clinical signs suggestive of primary renal
disease, vascular lesions or systemic disease; 3) patients without
an obvious cause for acute renal failure; and 4) those with sus-
pected drug toxicity. The histological findings are therefore more
likely to be found in patients with acute renal failure considered
atypical on clinical grounds. The lesions were predominantly
tubular in 24% of patients, predominantly interstitial in 13%,
glomerular in 29% and vascular in 32%. In three patients the
appearances were unclassifiable. No glomeruli were obtained in
only two patients (not discussed). Six patients suffered from
clinically significant bleeding, and in one patient with micro-
angiopathy, nephrectomy was necessary 30 days after the biopsy
because of prolonged bleeding. This complication was almost
confined to those patients with vascular lesions. We conclude
that renal biopsy is a valuable investigation in selected patients
with acute renal failure showing atypical features, aiding diag-
nosis, prognosis and treatment.
Effect of aluminium hydroxide therapy on calcium, phosphorus
and aluminium metabolism in normal subjects. J. Camm, V. A.
Luck, J. B. Eastwood and H. E. de Wardener. Department of
Medicine, Charing Cross Hospital Medical School, London. Alu-
minium hydroxide gel is widely used as an antacid. In patients
with renal failure, it is also used as a means of lowering the
plasma phosphorus concentration. Earlier studies have shown
that some of the ingested aluminium is absorbed. In eight patients
with renal failure given 75 to 150 ml of aluminium hydroxide,
there was a positive balance of 100 to 568 mg of aluminium/day.
A further finding was that, although there was a consistent
fall in plasma phosphorus, the change in phosphorus balance
could be in either direction or not change at all. In the present
study, aluminium hydroxide gel, 100 mI/day, was administered
to five normal subjects. Observations were made on calcium,
phosphorus and aluminium metabolism. There was a slight rise
in plasma calcium but no change in calcium balance. The fasting
plasma phosphorus concentration showed no change or a small
rise. There was a large rise in fecal phosphorus but, because of a
larger fall in urinary phosphorus, the balance of phosphorus
tended to become more positive (or less negative) than that of
the control period. The fall in urinary phosphorus, apparently
occurring without a fall in fasting serum phosphorus, required
explanation. Further studies of plasma phosphorus showed that
during the daytime, when aluminium hydroxide was being taken,
there was a fall in plasma phosphorus. This fall was more marked
than during the control period. The amount of aluminium ab-
sorbed varied between 7 and 96 mg/day. This was considerably
less than the amount of aluminium absorbed by the patients with
chronic renal failure, 2P <0.01. This difference may be explained
by the difference in phosphorus intake in the two groups.
Hemosiderosis due to parenteral administration of iron during
regular hemodialysis: Treatment with desferrioxamine. L. R. I.
Baker, B. Brozovic, W. R. Cattell, J. M. McAlister and C. C.
Nimmon. Department of Nephrology, St. Bartholomew's Hospital,
London. A 53-yr-old woman with chronic glomerulonephritis
commenced regular hemodialysis (3 x 10 hr/week, using a Kiil
dialyzer) in April, 1967. She received 5 ml of Ferrivenin i.v.
thrice-weekly for the next 15 months, corresponding to approxi-
mately 19 g of elemental iron. Two pints of blood were trans-
fused. Hepatosplenomegaly (liver, 12 cm; spleen, 6 cm) was
noted in December, 1972. Liver biopsy revealed gross hemosi-
derosis (iron content, 2407 g/l00 g; upper limit of normal,
150 g/100 g) and moderate periportal increase in reticulin.
Liver architecture was preserved. Bone marrow iron stores were
increased. After initial experiments with three different dose
schedules, 2 g of deferoxamine was infused during the first three
hours of each dialysis during the next 12 months. Iron removal
during dialysis—which occurred predominantly during the first
six hours of treatment—will be described. During the 12 months
of treatment, serum iron and TIBC increased. A sharp decline in
59Fe half-life occurred (before treatment, 7.0 yr; during treat-
ment, 1.4 and 0.6 yr). The effect of treatment upon liver iron
content and morphology will be described.
Atypical nondiabetic proteinuria and renal failure in patients
with diabetes mellitus. J. A. H. Wass, Victor Parsons, P. J. Watkins
and F. E. Dische. Six patients with proven diabetes mellitus, four
insulin-dependent, two transiently so, presented with proteinuria
and varieties of renal failure. Clinical presentation, absence of
advanced retinopathy and renal biopsy provided evidence that
diabetic patients are prone to similar glomerulopathies with and
without the Kimmel-Stiel-Wilson lesions. The importance of
renal biopsy diagnosis is emphasized as the prognosis and
management of such patients may be entirely different from the
conventional approach to patients with end-stage diabetic
glomerular disease.
